A Study to Investigate the Safety and Efficacy of Emapalumab, an Anti-IFN-gamma mAb in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD) Developing Macrophage Activation Syndrome/Secondary HLH (MAS/sHLH)

Macrophage Activation Syndrome Clinical Trial

Official title:
A Pilot, Open-label, Single Arm, Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous Administrations of Emapalumab, an Anti-interferon Gamma (Anti-IFNγ) Monoclonal Antibody, in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD) Developing Macrophage Activation Syndrome/Secondary HLH (MAS/sHLH)

Status Completed

Clinical Trial Summary

Macrophage Activation Syndrome (MAS) is a rare, life-threatening condition characterized by uncontrolled hyperinflammation which may develop on the background of systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD). Emapalumab is a monoclonal antibody neutralizing interferon-gamma (IFN-gamma), a key cytokine which contributes to the inflammation and tissue damage seen in MAS. The purpose of this study is to assess the safety, tolerability and efficacy of emapalumab in sJIA or AOSD participants developing MAS, presenting an inadequate response to high dose glucocorticoid treatment.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03311854
Study type	Interventional
Source	Swedish Orphan Biovitrum
Contact
Status	Completed
Phase	Phase 2
Start date	February 20, 2018
Completion date	May 19, 2020

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT03721809` - Characterization of the Inflammatory Profile of Patients With Macrophage Activation Syndrome Secondary to Bacterial Sepsis	N/A
Active, not recruiting	`NCT02780583` - Treatment of Macrophage Activation Syndrome (MAS) With Anakinra	Phase 1
Active, not recruiting	`NCT01966367` - CD34+ (Non-Malignant) Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation	Phase 1/Phase 2
Enrolling by invitation	`NCT01095146` - New Candidate Criteria for Diagnosis of Macrophage Activation Syndrome	N/A
Recruiting	`NCT02569463` - Low-dose IL-2 ( Interleukin-2) Treatment in Macrophage Activation Syndrome（MAS）	Phase 1/Phase 2
Not yet recruiting	`NCT05137496` - Ruxolitinib and Methylprednisolone as a First-line Treatment for Macrophage Activation Syndrome	Phase 3
Active, not recruiting	`NCT03827343` - Retrospective Study of Immunotherapy Related Toxicities and Factors Impacting Outcomes in Children and Adults With Cancer
Recruiting	`NCT05611710` - Anakinra in Dengue With Hyperinflammation ( AnaDen )	Phase 2
Recruiting	`NCT05001737` - Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE	Phase 3
Completed	`NCT03332225` - A Trial of Validation and Restoration of Immune Dysfunction in Severe Infections and Sepsis	Phase 2
Recruiting	`NCT06339177` - Hemophagocytic Lymphohistiocytosis (HLH) Evaluation and Research of Clinical, ImmUnoLogic and TranscriptomE Study
Completed	`NCT04339712` - Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction	Phase 2